SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the FDAs upcoming decision on Capricors deramiocel for Duchenne muscular dystrophy, with traders citing the amended upper-limb data, rare-disease policy discussions and recent launch-related hiring as reasons for optimism. Others caution that approval is uncertain given the prior negative review and continuing questions about the evidence.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Precigens strong quarterly results and rapid PAPZIMEOS commercial uptake are driving attention, with traders highlighting the companys return to profitability and potential for further growth. The upbeat reaction is accompanied by short-squeeze speculation and interest in upcoming PRGN-2009 data and European expansion.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A run to a 52-week high has traders positioning around the expected Q3 earnings report, with BRIUMVIs sales growth supporting optimism. Buyout rumors and heavy short interest are fueling squeeze speculation, though some traders see earnings expectationsnot a confirmed acquisitionas the main driver.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths post-TDAPA Medicare add-on could fall sharply after Q1 2027 has fueled concerns about pricing and CorMedix revenue amid a steep selloff. Traders dispute whether DaVitas preliminary outlook signals a broader reimbursement decline, pointing to CMSs published estimate, while others criticize management for not clarifying the potential impact.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL leukemia trial reached its prespecified 80th death event, triggering final analysis and putting the GPS survival readout at the center of discussion. Traders are divided between optimism about a strong result and concerns about the control arm and trial design, while shares have come under pressure ahead of the binary catalyst.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is under pressure after a steep decline, with traders focused on analyst price-target cuts and uncertainty ahead of its earnings report, as well as concerns about digital-ad growth. Bulls argue the selloff is disconnected from the companys profitability and growth, while bears warn of more downside if results or guidance disappoint; some also point to broader tech-market weakness.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp technology and AI-linked selloffintensified by Intels weak outlook and concerns about returns on heavy AI investmentis driving attention to QQQ. Traders are split between warning of more downside and treating the drop as an oversold dip with potential for a rebound.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

SMH is under pressure amid a semiconductor and tech selloff, as traders question whether heavy AI infrastructure spending will generate adequate returns; weak Intel guidance and concerns about Amazons elevated capex are cited as contributing pressures. The community is divided between expecting a deeper unwind in the AI trade and seeing oversold conditions and technical support as possible grounds for a bounce.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas strong quarterly results and raised outlook, alongside expectations that AI agents will increase demand for identity security, fueled a sharp rally. Traders are now debating whether the growth outlook justifies the valuation, with some taking profits or positioning for a pullback.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons stronger-than-expected third-quarter results, supported by growth in Eylea HD and Sanofi collaboration revenue from Dupixent, drove a sharp share-price gain. Traders largely celebrated the earnings beat and breakout, while some pointed to the upcoming cemdisiran decision as another potential catalyst.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kyndryl Holdings, Inc. (KD) Falls More Steeply Than Broader Market: What Investors Need to Know

Kyndryl Holdings, Inc. (KD) closed the most recent trading day at $13.94, moving 1.06% from the previous trading session.

Kyndryl Opens New Cyber Defense Operations Center in Paris

Kyndryl Opens New Cyber Defense Operations Center in Paris Kyndryl Opens New Cyber Defense Operations Center in ParisPR NewswirePARIS, Oct. 27, 2026 First-of-its-kind Kyndryl center in Europe reinforces strengths indata, AI and cyber resilience across the regionNew center delivers AI-enabled...

Kyndryl Holdings, Inc. (KD) Suffers a Larger Drop Than the General Market: Key Insights

Kyndryl Holdings, Inc. (KD) closed at $14.76 in the latest trading session, marking a -2.89% move from the prior day.

Kyndryl Named a Leader in the IDC MarketScape for Worldwide Digital Workplace Services 2026

Kyndryl Named a Leader in the IDC MarketScape for Worldwide Digital Workplace Services 2026 Kyndryl Named a Leader in the IDC MarketScape for Worldwide Digital Workplace Services 2026PR NewswireNEW YORK, Oct. 20, 2026 NEW YORK, Oct. 20, 2026 /PRNewswire/ -- Kyndryl (NYSE: KD), a leading provider of...

Kyndryl, Toyota Systems and Toyota Finance Modernize IT Operations with Agentic AI

Kyndryl, Toyota Systems and Toyota Finance Modernize IT Operations with Agentic AI Kyndryl, Toyota Systems and Toyota Finance Modernize IT Operations with Agentic AIPR NewswireNEW YORK and TOKYO, Oct. 14, 2026AI agents drive faster, higher-quality outcomes across infrastructure design and...

Kyndryl earns 21 Brandon Hall Group HCM Excellence Awards focused on integrity training and skill building

Kyndryl earns 21 Brandon Hall Group HCM Excellence Awards focused on integrity training and skill building Kyndryl earns 21 Brandon Hall Group HCM Excellence Awards focused on integrity training and skill buildingPR NewswireNEW YORK, Oct. 13, 2026Recognition includes five Gold awards, demonstrating...

KYNDRYL TO RELEASE QUARTERLY RESULTS ON NOVEMBER 4, 2026

KYNDRYL TO RELEASE QUARTERLY RESULTS ON NOVEMBER 4, 2026 KYNDRYL TO RELEASE QUARTERLY RESULTS ON NOVEMBER 4, 2026PR NewswireNEW YORK, Oct. 12, 2026NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kyndryl (NYSE: KD), a leading provider of mission-critical enterprise technology services, todayannounced that...

Kyndryl Holdings, Inc. (KD) Stock Falls Amid Market Uptick: What Investors Need to Know

Kyndryl Holdings, Inc. (KD) concluded the recent trading session at $11.75, signifying a -1.09% move from its prior day's close.

Kyndryl and WPP Expand Strategic Partnership to Drive Enterprise Transformation, Marketing Growth and Joint Go-to-Market Innovation

Kyndryl and WPP Expand Strategic Partnership to Drive Enterprise Transformation, Marketing Growth and Joint Go-to-Market Innovation Kyndryl and WPP Expand Strategic Partnership to Drive Enterprise Transformation, Marketing Growth and Joint Go-to-Market InnovationPR NewswireLONDON, Oct. 6, 2026WPP...

Kyndryl Holdings, Inc. (KD) Stock Sinks As Market Gains: Here's Why

In the closing of the recent trading day, Kyndryl Holdings, Inc. (KD) stood at $11.56, denoting a -4.62% move from the preceding trading day.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Nasdaq, S&P 500 Futures Subdued After Dow Closes Above 50,000: Why TSLA, RBLX, TSM, HOOD, KD Are On Traders' Radar Today

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Early futures action suggests traders were shifting focus from index-level momentum to stock-specific catalysts.</li><li>On the economic front, investors will be watching for December retail sales data.</li><li>Fintech stocks are seeing renewed chatter after YouTube star MrBeast revealed a push into financial services via the acquisition of the fintech app Step.</li></ul>U.S. stock futures were&nbsp;muted early Tuesday after the Dow’s record close above 50,000 in the previous trading session.As of 3:00 a.m. ET on Tuesday, Dow futures were flat with a positive bias, while the S&amp;P 500, Nasdaq and Russell 2000 futures were flat, with a negative bias.&nbsp;&nbsp;Meanwhile, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, has remained ‘bearish’, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, slipped to ‘bearish’ from ‘neutral’ a day ago amid high message volumes.&nbsp;Trending Stocks To Watch Tesla (TSLA):&nbsp;The Elon Musk-led EV company continues to see senior leadership departures, with the latest being Raj Jegannathan, who left after 13 years.Amazon (AMZN):&nbsp;The company is reportedly planning a new marketplace that would allow publishers to market content to AI firms.Meta Platforms (META) and Alphabet (GOOGL):&nbsp;Big tech faces renewed legal scrutiny, with allegations that their platforms were designed to addict children. A trial is underway in California.&nbsp;TSMC (TSM):&nbsp;It has reported 37% year-over-year growth in January revenue. Reports also suggest that the U.S. government may exempt it from tariffs on semiconductors.&nbsp;Databricks:&nbsp;Has raised $5 billion in fresh funding, valuing the company at $134 billion and intensifying comparisons with Snowflake.&nbsp;Kyndryl (KD):&nbsp;The stock is in focus after a JPMorgan double-downgrade, following a surprise CFO exit and accounting reviewRoblox (RBLX):&nbsp;The Australian government has called a meeting with the gaming platform over reports of child grooming and exposure to graphic content on the platform. Meanwhile,&nbsp;Cathie Wood’s ARK Invest has bought more shares in Roblox and Bullish.Keep an eye on&nbsp;Robinhood, SoFi, and Block:&nbsp;YouTube star "MrBeast" has announced a push into financial technology with the acquisition of the fintech app Step.Other tickers trending on Stocktwits at the time of writing included Snap Inc (SNAP), Pagaya Technologies (PGY), Innodata (INOD), and Wave Life Sciences (WVE), among others.&nbsp;Other Catalysts To WatchOn the economic front, investors will be watching retail sales data for December, the employee cost index for Q4, and import and export price indexes.&nbsp; On the earnings radar, investors will also be watching for the quarterly reports from Coca-Cola (KO), CVS Health (CVS), Marriott (MAR), Spotify (SPOT), Datadog (DDOG), Fiserv (FISV), Incyte (INCY), Oscar Health (OSCR), Quest Diagnostics (DGX), Zimmer Biomet (ZBH), Hasbro (HAS), Saia (SAIA), Harley-Davidson (HOG), Robinhood (HOOD), and Cloudflare (NET), among others.For updates and corrections, email newsroom[at]stocktwits[dot]com

Retail chatter on Stocktwits shows ‘ bearish’ sentiment for the SPY ETF, as well as tech-heavy QQQ. 

Robinhood Markets Inc

Roblox Corp.

Taiwan Semiconductor Manufacturing - ADR

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

KD News